Prime Medicine Focuses on Liver Franchise with $191.4M Cash Runway
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy PRME?
Source: Yahoo Finance
- Financial Overview: Prime Medicine ended fiscal year 2025 with $191.4 million in cash and equivalents, ensuring financial stability through 2027 despite a net loss of $201.1 million, highlighting challenges in financial management.
- Stable R&D Spending: The company maintained R&D expenses at $160.6 million, indicating a commitment to advancing high-priority clinical milestones while optimizing its workforce amidst financial pressures, particularly in liver-related projects.
- Clinical Progress and Regulatory Path: Prime Medicine plans to submit IND or CTA for Wilson Disease in H1 2026 and for AATD in mid-2026, with initial clinical data for both expected in 2027, showcasing its strategic focus on liver disease treatments.
- FDA Accelerated Approval: The company is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate PM359, based on positive Phase 1/2 data published in the New England Journal of Medicine, which could make PM359 the first Prime Edited therapy available to patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRME
Wall Street analysts forecast PRME stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 4.050
Low
4.25
Averages
6.06
High
9.00
Current: 4.050
Low
4.25
Averages
6.06
High
9.00
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prime Medicine Focuses on Liver Franchise with $191.4M Cash Runway
- Financial Overview: Prime Medicine ended fiscal year 2025 with $191.4 million in cash and equivalents, ensuring financial stability through 2027 despite a net loss of $201.1 million, highlighting challenges in financial management.
- Stable R&D Spending: The company maintained R&D expenses at $160.6 million, indicating a commitment to advancing high-priority clinical milestones while optimizing its workforce amidst financial pressures, particularly in liver-related projects.
- Clinical Progress and Regulatory Path: Prime Medicine plans to submit IND or CTA for Wilson Disease in H1 2026 and for AATD in mid-2026, with initial clinical data for both expected in 2027, showcasing its strategic focus on liver disease treatments.
- FDA Accelerated Approval: The company is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate PM359, based on positive Phase 1/2 data published in the New England Journal of Medicine, which could make PM359 the first Prime Edited therapy available to patients.
See More
Prime Medicine Reports FY 2023 Financial Results
- Financial Performance: Prime Medicine reported a FY GAAP EPS of -$1.35, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Details: The company generated revenue of $4.63 million, which, while showing some growth, fell short of market expectations, potentially putting pressure on the stock price.
- Market Reaction: Following the Q4 updates, Prime Medicine's stock slipped, reflecting investor concerns over financial performance that could impact future fundraising capabilities.
- Investment Rating: Despite these challenges, analysts maintain a 'Buy' rating on Prime Medicine, suggesting optimism regarding its solidified catalysts for Wilson's disease and other potential developments.
See More
Prime Medicine Reports Q4 2025 Results and Future Milestones
- Financial Performance: Prime Medicine reported a Q4 2025 net loss of $0.24 per share with revenue of $838K, both falling short of market expectations of $0.26 and $2.1M, indicating challenges in revenue growth.
- Cash Flow Status: As of December 31, Prime's total cash, cash equivalents, investments, and restricted cash reached $191.4M, reflecting a ~6% year-over-year decline, although the liquidity level is sufficient to fund operations and capital expenses through 2027, future funding needs remain a concern.
- FDA Accelerated Approval Plans: The company plans to submit a Biologics License Application for its gene editing therapy PM359 targeting chronic granulomatous disease to the FDA, with existing clinical data expected to support accelerated approval, which could significantly enhance its market position in the rare disease sector.
- Clinical Research Progress: For liver-focused programs targeting Wilson's disease and Alpha-1 Antitrypsin Deficiency, Prime expects to apply for an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) in H1 2026 and mid-2026, respectively, with topline data from both programs scheduled for release next year, further advancing the company's research agenda.
See More
Prime Medicine to Participate in Three Major Conferences
- Conference Schedule: Prime Medicine will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its latest advancements in gene editing technology during a fireside chat.
- One-on-One Meetings: Company management will host one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami Beach, aiming to engage deeply with investors and explore potential financing opportunities.
- Technology Showcase: At the Citizens Life Sciences Conference on March 11, 2026, Prime Medicine will conduct another fireside chat to elaborate on its unique Prime Editing platform and its potential applications in gene therapy.
- Live Webcasts: All fireside chats will be available via live webcasts on the company's website, with replays accessible for 90 days post-event, ensuring investors and the public can stay informed about key developments.
See More
Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032
- Market Growth Potential: The gene therapy market is projected to reach $36.55 billion by 2032, growing at a compound annual growth rate of 17.98%, indicating a rapid rise in demand for curative treatments that is attracting investor interest.
- FDA Approval of New Therapies: The FDA's approval of three transformative cell therapies in December marks a pivotal shift from experimental concepts to commercial reality, further propelling the strategic development of companies like Avant Technologies.
- Technological Innovation: Avant Technologies is developing a cell encapsulation technology in partnership with SGAustria that protects genetically modified cells from immune rejection, addressing the long-standing issue of diabetes patients relying on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Market Opportunity: With 589 million people globally living with diabetes, Avant Technologies is positioned to capitalize on a substantial market opportunity, projected to grow to 853 million by 2050, highlighting the urgent need for innovative treatment solutions.
See More
Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032
- Market Growth Potential: The gene therapy market is projected to reach $36.55 billion by 2032, growing at a compound annual rate of 17.98%, reflecting a surge in demand for curative treatments that drives investor confidence in functional cures.
- FDA Approval of New Therapies: The FDA's approval of three transformative cell therapies in December marks a shift from experimental concepts to commercial reality, providing new market opportunities for companies like Avant Technologies.
- Strategic Partnerships: Avant's collaboration with SGAustria focuses on developing cell-based therapies for type 1 and insulin-dependent type 2 diabetes using encapsulation technology to address immune rejection, which is expected to significantly enhance patient quality of life.
- Anti-Aging Therapy Development: Avant's second joint venture, Klothonova, partners with Austrianova to develop anti-aging therapies that restore circulating α-Klotho levels using genetically modified human cells, with potential markets spanning Alzheimer's disease and cardiovascular conditions.
See More
Prime Medicine Focuses on Liver Franchise with $191.4M Cash Runway
- Financial Overview: Prime Medicine ended fiscal year 2025 with $191.4 million in cash and equivalents, ensuring financial stability through 2027 despite a net loss of $201.1 million, highlighting challenges in financial management.
- Stable R&D Spending: The company maintained R&D expenses at $160.6 million, indicating a commitment to advancing high-priority clinical milestones while optimizing its workforce amidst financial pressures, particularly in liver-related projects.
- Clinical Progress and Regulatory Path: Prime Medicine plans to submit IND or CTA for Wilson Disease in H1 2026 and for AATD in mid-2026, with initial clinical data for both expected in 2027, showcasing its strategic focus on liver disease treatments.
- FDA Accelerated Approval: The company is actively engaging with the FDA to pursue an accelerated approval pathway for its CGD candidate PM359, based on positive Phase 1/2 data published in the New England Journal of Medicine, which could make PM359 the first Prime Edited therapy available to patients.
See More
Prime Medicine Reports FY 2023 Financial Results
- Financial Performance: Prime Medicine reported a FY GAAP EPS of -$1.35, indicating challenges in profitability that may affect investor confidence moving forward.
- Revenue Details: The company generated revenue of $4.63 million, which, while showing some growth, fell short of market expectations, potentially putting pressure on the stock price.
- Market Reaction: Following the Q4 updates, Prime Medicine's stock slipped, reflecting investor concerns over financial performance that could impact future fundraising capabilities.
- Investment Rating: Despite these challenges, analysts maintain a 'Buy' rating on Prime Medicine, suggesting optimism regarding its solidified catalysts for Wilson's disease and other potential developments.
See More
Prime Medicine Reports Q4 2025 Results and Future Milestones
- Financial Performance: Prime Medicine reported a Q4 2025 net loss of $0.24 per share with revenue of $838K, both falling short of market expectations of $0.26 and $2.1M, indicating challenges in revenue growth.
- Cash Flow Status: As of December 31, Prime's total cash, cash equivalents, investments, and restricted cash reached $191.4M, reflecting a ~6% year-over-year decline, although the liquidity level is sufficient to fund operations and capital expenses through 2027, future funding needs remain a concern.
- FDA Accelerated Approval Plans: The company plans to submit a Biologics License Application for its gene editing therapy PM359 targeting chronic granulomatous disease to the FDA, with existing clinical data expected to support accelerated approval, which could significantly enhance its market position in the rare disease sector.
- Clinical Research Progress: For liver-focused programs targeting Wilson's disease and Alpha-1 Antitrypsin Deficiency, Prime expects to apply for an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) in H1 2026 and mid-2026, respectively, with topline data from both programs scheduled for release next year, further advancing the company's research agenda.
See More
Prime Medicine to Participate in Three Major Conferences
- Conference Schedule: Prime Medicine will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its latest advancements in gene editing technology during a fireside chat.
- One-on-One Meetings: Company management will host one-on-one meetings at the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami Beach, aiming to engage deeply with investors and explore potential financing opportunities.
- Technology Showcase: At the Citizens Life Sciences Conference on March 11, 2026, Prime Medicine will conduct another fireside chat to elaborate on its unique Prime Editing platform and its potential applications in gene therapy.
- Live Webcasts: All fireside chats will be available via live webcasts on the company's website, with replays accessible for 90 days post-event, ensuring investors and the public can stay informed about key developments.
See More
Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032
- Market Growth Potential: The gene therapy market is projected to reach $36.55 billion by 2032, growing at a compound annual growth rate of 17.98%, indicating a rapid rise in demand for curative treatments that is attracting investor interest.
- FDA Approval of New Therapies: The FDA's approval of three transformative cell therapies in December marks a pivotal shift from experimental concepts to commercial reality, further propelling the strategic development of companies like Avant Technologies.
- Technological Innovation: Avant Technologies is developing a cell encapsulation technology in partnership with SGAustria that protects genetically modified cells from immune rejection, addressing the long-standing issue of diabetes patients relying on immunosuppressive drugs, thereby enhancing treatment safety and efficacy.
- Market Opportunity: With 589 million people globally living with diabetes, Avant Technologies is positioned to capitalize on a substantial market opportunity, projected to grow to 853 million by 2050, highlighting the urgent need for innovative treatment solutions.
See More
Avant Technologies Drives Gene Therapy Market to $36.55 Billion by 2032
- Market Growth Potential: The gene therapy market is projected to reach $36.55 billion by 2032, growing at a compound annual rate of 17.98%, reflecting a surge in demand for curative treatments that drives investor confidence in functional cures.
- FDA Approval of New Therapies: The FDA's approval of three transformative cell therapies in December marks a shift from experimental concepts to commercial reality, providing new market opportunities for companies like Avant Technologies.
- Strategic Partnerships: Avant's collaboration with SGAustria focuses on developing cell-based therapies for type 1 and insulin-dependent type 2 diabetes using encapsulation technology to address immune rejection, which is expected to significantly enhance patient quality of life.
- Anti-Aging Therapy Development: Avant's second joint venture, Klothonova, partners with Austrianova to develop anti-aging therapies that restore circulating α-Klotho levels using genetically modified human cells, with potential markets spanning Alzheimer's disease and cardiovascular conditions.
See More
